These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15623646

  • 21. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 22. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [Abstract] [Full Text] [Related]

  • 23. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjögreen K, Wingårdh K, Strand SE.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [Abstract] [Full Text] [Related]

  • 24. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.
    Clin Cancer Res; 2009 Jun 15; 15(12):4038-45. PubMed ID: 19509168
    [Abstract] [Full Text] [Related]

  • 25. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M, Rybak RJ, Choi Y, Greenberg SJ, Barcos M, Kawata A, Matsuno F, Tsai H, Seon BK.
    Cancer Res; 1997 Feb 15; 57(4):678-85. PubMed ID: 9044845
    [Abstract] [Full Text] [Related]

  • 26. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
    Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, Law CL, Izui S.
    Arthritis Rheum; 2003 Jun 15; 48(6):1612-21. PubMed ID: 12794829
    [Abstract] [Full Text] [Related]

  • 27. Constitutive endocytosis and degradation of CD22 by human B cells.
    Shan D, Press OW.
    J Immunol; 1995 May 01; 154(9):4466-75. PubMed ID: 7722303
    [Abstract] [Full Text] [Related]

  • 28. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ.
    Int J Cancer Suppl; 1992 May 01; 7():73-7. PubMed ID: 1428411
    [Abstract] [Full Text] [Related]

  • 29. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA, Brechbiel MW, Burns LJ, Panoskaltsis-Mortari A, Dusenbery KE, Clohisy DR, Vitetta ES.
    Clin Cancer Res; 2005 Nov 01; 11(21):7920-8. PubMed ID: 16278417
    [Abstract] [Full Text] [Related]

  • 30. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
    Perfetti V, Vignarelli MC, Bellotti V, Glennie MJ, Zorzoli I, Ubbiali P, Obici L, Massa M, Ippoliti G, Ascari E, Merlini G.
    Lab Invest; 1997 Oct 01; 77(4):333-44. PubMed ID: 9354768
    [Abstract] [Full Text] [Related]

  • 31. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 32. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.
    Clin Cancer Res; 2005 Jul 15; 11(14):5215-22. PubMed ID: 16033839
    [Abstract] [Full Text] [Related]

  • 33. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP, Goldenberg DM.
    Oncogene; 2007 May 28; 26(25):3704-13. PubMed ID: 17530024
    [Abstract] [Full Text] [Related]

  • 34. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.
    J Nucl Med; 2009 Mar 28; 50(3):444-53. PubMed ID: 19223402
    [Abstract] [Full Text] [Related]

  • 35. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
    Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2001 Jun 28; 7(6):1505-10. PubMed ID: 11410483
    [Abstract] [Full Text] [Related]

  • 36. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 28; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 37. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
    Huang YW, Richardson JA, Vitetta ES.
    Cancer Res; 1995 Feb 01; 55(3):610-6. PubMed ID: 7834632
    [Abstract] [Full Text] [Related]

  • 38. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.
    Arndt MA, Krauss J, Rybak SM.
    FEBS Lett; 2004 Dec 17; 578(3):257-61. PubMed ID: 15589829
    [Abstract] [Full Text] [Related]

  • 39. CD22.
    Engel P.
    J Biol Regul Homeost Agents; 2000 Dec 17; 14(4):295-8. PubMed ID: 11215824
    [No Abstract] [Full Text] [Related]

  • 40. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
    Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM.
    Clin Cancer Res; 2005 Jul 15; 11(14):5257-64. PubMed ID: 16033844
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.